Search | Clinical Trials Finder

Conditions: Anal Neoplasm
Interventions: VGX-3100, CELLECTRA™ 5PSP; Biological · Device
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Multiple Myeloma
Interventions: Evomela, Next Generation Sequencing, Prochlorperazine, Acetaminophen, Diphenhydramine; Drug · Device
Lead sponsor: Koen van Besien; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Head Injury Trauma, Traumatic Brain Injury, Mild
Interventions: Clinical pathway 1: Guidelines plus biomarkers, Clinical guidelines only; Diagnostic Test
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: Sylmar, California • Torrance, California • Clinton Township, Michigan + 2 more

Conditions: Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
Interventions: Droxidopa, Placebo Oral Tablet; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 50 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Neutropenia, Infection
Interventions: Standard antimicrobial therapy, Granulocyte transfusions, G-CSF/dexamethasone, Apheresis machine; Drug · Biological · Device
Lead sponsor: Carelon Research; Other
Eligibility: Not listed
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 13
States / cities: Iowa City, Iowa • Baltimore, Maryland • Boston, Massachusetts + 9 more

Conditions: Long COVID Fatigue
Interventions: Ketogenic Metabolic Therapy, Lifestyle Intervention; Other · Behavioral
Lead sponsor: National University of Natural Medicine; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Diffuse Astrocytoma, Glioblastoma, IDH-Wildtype, Malignant Glioma
Interventions: Biospecimen Collection, Eflornithine, Lumbar Puncture, Magnetic Resonance Imaging, Retifanlimab, Tumor Resection; Procedure · Drug · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type 2 Diabetes Mellitus
Interventions: South Beach Diet with South Beach Diet Products, American Diabetes Association Diabetes Meal Plan; Behavioral
Lead sponsor: Mondelēz International, Inc.; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Northridge, California • Bradenton, Florida • Miami, Florida + 3 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Euglycemic clamp (normal blood sugar clamp) for 4 hours, hyperglycemic clamp (elevated blood sugar to 300) for 4 hours; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Leukemia
Interventions: Alemtuzumab, Rituximab, Sargramostim; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Leukemia, Lymphoma
Interventions: filgrastim, rituximab, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, methotrexate, prednisone, vincristine sulfate, Allopurinol; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 16 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2014
U.S. locations: 31
States / cities: San Diego, California • Lewes, Delaware • Newark, Delaware + 25 more

Conditions: Schizophrenia, Bipolar Disorder
Interventions: Ketogenic diet; Other
Lead sponsor: Northern California Institute of Research and Education; Other
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Neuroblastoma, Central Nervous System Tumors, Lymphomas, Wilms Tumor
Interventions: Stem Cell Transplantation, Busulfan, Melphalan; Procedure · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 25 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions: Cladribine, Cytarabine, Filgrastim, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Mitoxantrone, Sorafenib; Drug · Biological · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 60 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: Autologous Dendritic Cells (DC), Fludarabine, Autologous Lymphocyte Infusion (ALI); Biological · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 16 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Neuroblastoma
Interventions: Filgrastim, Carboplatin, Etoposide, Melphalan, Peripheral blood stem cell infusion, 131I-MIBG, Radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: 1 Year to 29 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 14
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more

Conditions: Adult Anaplastic Astrocytoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions: ixabepilone, pharmacological study, Anticonvulsant; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 5
States / cities: Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 2 more

Conditions: Leukemia, MDS, Myelofibrosis, Lymphoma
Interventions: Fludarabine, Cyclophosphamide, Mesna, Total Body Irradiation, Hematopoietic stem cell infusion, Tacrolimus, Mycophenolate, G-CSF; Drug · Radiation · Other
Lead sponsor: Rafic Farah, MD; Other
Eligibility: 18 Years to 70 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Preterm Birth
Interventions: Enhanced Intravenous Nutrition, Standard Intravenous Nutrition; Other
Lead sponsor: University of Minnesota; Other
Eligibility: Up to 30 Weeks
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Satiety in Healthy Volunteers
Interventions: Erythritol, Aspartame; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 40 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Kidney Transplantation
Interventions: Rabbit Antithymocyte Globulin, Velcade, Rituxan; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Food Protein-Induced Enterocolitis Syndrome
Interventions: Supervised Low-Dose Oral Food Challenge (OFC), At-Home Low-Dose Oral Food Challenge (OFC), Supervised High-Dose Oral Food Challenge (OFC); Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 1 Year to 60 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: New York, New York

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions: filgrastim, clofarabine, melphalan, mycophenolate mofetil, tacrolimus, thiotepa, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 0 Years to 54 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Ulcer, Leg Ulcer, Varicose Ulcer, Pathologic Processes, Skin Ulcer, Skin Diseases, Vascular Diseases, Cardiovascular Diseases
Interventions: Placebo, VF001-DP LD, VF001-DP HD; Biological
Lead sponsor: Factor Therapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 17
States / cities: Carlsbad, California • Fresno, California • Laguna Hills, California + 10 more

Search by objective public record fields.

VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2

Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma

The PIONEER Comparative Effectiveness Study - Project 2

Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism

Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)

Fully Remote, Telehealth-based Ketogenic Metabolic Therapy for Long COVID

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Effect of South Beach Diet (SBD™) Using SBD™ Products Compared to the American Diabetic Association (ADA) Diabetes Meal Plan on Body Weight and Satiety in Diabetic Women

Tissue-Specific Metabolic Reprogramming in Diabetic Complications

Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia

Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia

Can Neural Network Instability in Schizophrenia be Improved With a Very Low Carbohydrate Ketogenic Diet?

Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Dendritic Cell Vaccination During Lymphoid Reconstruction

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas

Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

Enhanced Nutrition for Preterm Infants

Assessment of Satiety Following Oral Administration of an Erythritol Sweetened Beverage

Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients

Immunologic Basis of Food Protein-Induced Enterocolitis Syndrome

Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

Study of VF001-DP in Patients With Chronic Venous Leg Ulcers